Earnings + Strategic Update (Merger Progress)
Aster DM Healthcare Delivers Strong Q4 FY26; Revenue Up 18% YoY, EBITDA Growth Continues
NSE
asterdm
BSE
540975
Aster DM Healthcare reported strong Q4 FY26 results with 18% YoY revenue growth and 31% YoY EBITDA growth (ex-Kasaragod), supported by higher patient volumes, specialty mix improvement, and operational efficiency. The merger with Quality Care India Ltd (QCIL) is progressing toward completion
PRICE-SENSITIVE TRIGGER
Event: Q4 & FY26 Financial Results Announcement
Type: Earnings + Strategic Update (Merger Progress)
Impact: Positive
Immediate Effect: Improved margins and strong volume growth enhance earnings visibility, while merger progress adds long-term re-rating potential.
Key Metrics:
Key Metrics (Standalone – Q4 FY26):
- Revenue: ₹1,182 crore (+18% YoY)
- Operating EBITDA (ex-Kasaragod): ₹253 crore (+31% YoY)
- EBITDA Margin: 21.7% (vs 19.3% YoY)
- Normalised PAT: ₹153 crore (+45% YoY)
Combined (Aster + QCIL Proforma):
- Revenue: ₹2,361 crore (+18% YoY)
- Operating EBITDA: ₹517 crore (+25% YoY)
- EBITDA Margin: 21.9%
Highlight:
- EBITDA Growth: +31% YoY (Standalone) — strong operating leverage
What Happened ?
Aster DM Healthcare announced its Q4 FY26 results, reporting strong growth across hospitals, clinics, and labs segments.
The company also highlighted:
- Strong patient volume growth
- Margin expansion across clusters
- Significant progress in merger with Quality Care India Ltd
key highlights
Core Business Performance:
- ARPP (Average Revenue Per Patient) increased by 9% YoY
- Total patient volume grew 15% YoY
- IP volume growth: +7% YoY
- OP volume growth: +15% YoY
- Strong growth in cardiac (+25%) and oncology (+23%) segments
Labs & Specialty Growth:
- Aster Labs revenue grew 18% YoY
- EBITDA surged 181% YoY
- Margin improved to 14.7% (vs 6.2% YoY)
Cluster-wise Performance:
- Kerala revenue growth: +21% YoY
- Andhra & Telangana revenue growth: +30% YoY
- Kerala EBITDA growth: +27% YoY
- Karnataka & Maharashtra EBITDA growth: +25% YoY
- Andhra & Telangana EBITDA growth: +113% YoY
Merger Update (Key Strategic Trigger):
- Preferential allotment completed (~3.6% stake to Blackstone & TPG)
- CCI approval received
- Stock exchanges issued no-objection
- Shareholders & creditors approved merger (96.68% votes in favor)
- Final approval pending NCLT
- Expected completion: Q1 FY27
Note:
Post-merger entity will have >10,600 beds with strong expansion pipeline
Risk Analysis
Key Risks
- Merger completion subject to regulatory approvals (NCLT)
- Integration risks post-merger
- Healthcare cost inflation
- Dependence on occupancy and ARPP growth
- Regional concentration risk (Kerala heavy exposure)
Worst Case Scenario
- Delay in merger or integration challenges could impact valuation upside and operational synergies
Risk Level: Medium
Company Commentary
- Strong execution led to consistent revenue growth
- EBITDA growth driven by operating leverage and cost discipline
- Merger progressing with strong shareholder support
- Aim to build a top-tier integrated healthcare platform in India
- Capacity expansion to >15,500 beds in near term
Official Exchange Filing: Aster DM Healthcare Limited